Highest-materiality recent filing
HCA Q2 prelim revenue $20.23B, EPS $7.62; cuts FY2026 guidance on payer mix shift
Q2 2026 revenue $20.230B (+8.7% YoY); net income $1.699B ($7.62 diluted EPS) vs $1.653B ($6.83) in Q2 2025.
HCA Healthcare EVP & Chief Clinical Officer Michael Cuffe to step down Aug 31, 2026
Dr. Michael Cuffe to step down as EVP and Chief Clinical Officer effective August 31, 2026.
HCA Inc. issues $3B in senior notes across three tranches maturing 2031-2036
Issued $1B of 4.700% notes due 2031, $750M of 5.000% notes due 2033, and $1.25B of 5.300% notes due 2036.
HCA Q1 revenue up 4.3% to $19.1B; EPS rises 10.9% to $7.15; declares $0.78 dividend
Revenues $19.109B, net income $1.620B (+0.6% YoY); diluted EPS $7.15 (+10.9% YoY).
HCA Healthcare Q4 EPS $8.14 (up 44.6%), revenue $19.5B, $10B buyback authorized
Q4 revenue $19.513B (+6.7% YoY); net income $1.878B (+30.6%); adjusted EBITDA $4.114B (+10.8%).
HCA issues $3.25B senior notes: 4.30% 2030, 4.60% 2032, 4.90% 2035, 5.70% 2055
$500M 4.30% notes due 2030, $1B 4.60% due 2032, $1B 4.90% due 2035, $750M 5.70% due 2055.
HCA subsidiary proposes senior notes offering, plans to redeem $1.5B 5.875% notes due 2026
HCA Inc. proposes public offering of senior unsecured notes; terms (maturity, rate, amount) to be set at pricing.
HCA Healthcare Q3 EPS $6.96, revenue $19.2B, raises 2025 guidance
Diluted EPS $6.96 (up 42.6% YoY); net income $1.643B (up 29.4%).
HCA Q2 revenue $18.6B (+6.4%), EPS $6.83 (+23.5%); raises 2025 guidance
Revenue $18.605B (+6.4% YoY); net income $1.653B (+13.1% YoY).
HCA Healthcare Q1 revenue $18.3B, EPS $6.45, adjusted EBITDA $3.73B, reaffirms guidance
Revenue $18.321B (+5.7% YoY); net income $1.610B, diluted EPS $6.45 (vs $5.93 prior year).
HCA enters $8.0B unsecured revolver, terminates secured credit facilities
New $8.0B senior unsecured revolving credit facility with 5-year maturity dated Feb 20, 2025.
HCA subsidiary HCA Inc. proposes offering of senior notes; final terms (maturity, rate, amount) depend on market conditions.
HCA Q4 revenue $18.3B, EPS $5.63; 2025 EPS guidance $24.05-$25.85; $10B buyback authorized
Q4 revenue $18.285B (+5.7% YoY); net income $1.438B ($5.63 diluted EPS) vs $1.607B ($5.93) in 4Q23; includes $0.60/sh hurricane impact.
Revenue $17.487B (up 7.9% YoY), net income $1.270B (up 17.7%), diluted EPS $4.88 vs $3.91.
HCA Healthcare issues $3B in senior notes across three tranches with rates 5.45%-5.95%
$3B total: $750M 5.45% notes due 2031 (now $1.75B total), $1.25B 5.45% notes due 2034, $1B 5.95% notes due 2054.
HCA Q2 2024 rev $17.49B, EPS $5.53, raises FY guidance
Revenue $17.492B (+10.3% YoY); net income $1.461B ($5.53 diluted EPS) vs $1.193B ($4.29).
William B. Rutherford retires as EVP/CFO effective May 1, 2024; Christopher Wyatt succeeds as principal accounting officer.
HCA Q1 revenue up 11% to $17.34B, EPS $5.93; reaffirms FY guidance
Revenue $17.339B (+11.2% YoY); net income $1.591B ($5.93 diluted EPS) vs $1.363B ($4.85).
HCA issues $4.5B of senior notes across four tranches (2031-2064)
$1.0B of 5.450% notes due 2031, $1.3B of 5.600% notes due 2034, $1.5B of 6.000% notes due 2054, $0.7B of 6.100% notes due 2064.
HCA Healthcare issues $4.5B senior notes in four tranches with maturities from 2031 to 2064
$1.0B of 5.450% notes due 2031, $1.3B of 5.600% notes due 2034.
Q4 2023 revenue $17.303B (+11.6% YoY); net income $1.607B ($5.93 diluted EPS) vs $2.081B ($7.28) in Q4 2022, which included $1.326B gain.
HCA targets 4-6% EBITDA, 8-12% EPS growth over 5 yrs; 2024 within ranges
Adjusted EBITDA growth target of 4% to 6% annually over next five years.
HCA Healthcare Q3 revenue $16.21B, EPS $3.91; FY 2023 guidance revised; dividend $0.60
Revenue $16.213B (+8.3% YoY); net income $1.079B ($3.91 diluted EPS, flat vs $3.91 prior year).
HCA Healthcare Q2 2023 revenue $15.86B; EPS $4.29; raises 2023 guidance
Revenue $15.861B, up 7% YoY; net income $1.193B, diluted EPS $4.29 (vs $3.90).
HCA Healthcare issues $3.25B senior notes in three tranches
$1.0B of 5.200% Senior Notes due 2028, $1.25B of 5.500% due 2033, $1.0B of 5.900% due 2053.
HCA Healthcare Q1 EPS $4.85 beats prior year; raises 2023 revenue and profit guidance
Q1 revenues $15.591B (up 4.3% YoY); net income $1.363B, diluted EPS $4.85 vs $4.14.
HCA Healthcare Q4 net income $2.08B ($7.28 EPS); revenue $15.5B; new $3B buyback
Q4 revenue $15.50B (+2.9% YoY); net income $2.08B ($7.28 diluted EPS) incl $1.33B facility-sale gains.
HCA Healthcare promotes Jon Foster to EVP & COO; creates third operating group
Jon Foster, previously President of American Group, named EVP & COO effective January 1, 2023.
HCA Healthcare Q3 revenue down 2% to $14.97B; net income $1.13B ($3.91 EPS)
Revenue fell 2% YoY to $14.97B; net income $1.13B ($3.91 EPS) vs $2.27B ($7.00 EPS) prior year which included $1.05B sale gains.
HCA Healthcare Q2 2022 net income down 20% to $1.155B; EPS $3.90 vs $4.36 YoY
Revenue $14.820B (+2.7% YoY); net income $1.155B ($3.90 EPS) vs $1.450B ($4.36) in Q2 2021.
On June 15, 2026, Dr. Michael Cuffe and HCA Healthcare, Inc. (the “Company”) agreed that Dr. Cuffe will step down as Executive Vice President and Chief Clinical Officer effective August 31, 2026, and thereafter continue in a transitional role with the Company until February 2027.
Retirement of Meg G. Crofton from the
As previously announced, William B. Rutherford, HCA Healthcare, Inc.’s (the “Company’s”) Executive Vice President, Chief Financial Officer, principal financial officer and principal accounting officer notified the Company of his intent to retire, effective May 1, 2024.
In conjunction with Mr. Rutherford’s retirement, Christopher F. Wyatt, age 47, will succeed Mr. Rutherford as principal accounting officer, effective May 1, 2024.
William B. Rutherford intends to retire as Executive Vice President and Chief Financial Officer, effective May 1, 2024, and will therefore not participate in the Executive Officer PEP.
• 85% of base salary for Michael R. McAlevey, our Senior Vice President and Chief Legal Officer (to be increased to 100%, effective April 1, 2024, in connection with Mr. McAlevey’s appointment as Executive Vice President – Chief Legal and Administrative Officer).
On January 30, 2024, the Company announced that Michael A. Marks, age 54, will succeed Mr. Rutherford as Executive Vice President and Chief Financial Officer, effective May 1, 2024.
On January 24, 2024, William B. Rutherford notified the Company of his intent to retire from his position as Executive Vice President and Chief Financial Officer, effective May 1, 2024.
On October 20, 2022, the Board of Directors of HCA Healthcare, Inc. (the “Company”) appointed Jon M. Foster as the Executive Vice President and Chief Operating Officer of the Company effective January 1, 2023.
On August 15, 2022, Charles J. Hall, the President — National Group of HCA Healthcare, Inc. (the “Company”), informed the Company that he will retire from the Company, effective December 31, 2022.
On January 24, 2022, the Company’s Board of Directors (the “Board”), based on the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Andrea B. Smith to the Company’s Board effective January 26, 2022, increasing the number of directors on the Board from 10 to 11.
Dr. Jonathan B. Perlin, President - Clinical Operations Group and Chief Medical Officer, notified HCA Healthcare, Inc. (the “Company”) on September 16, 2021 that he had accepted the role of president and CEO of The Joint Commission and will assume his new role on March 1, 2022.
Max materiality 0.85 · Median 0.60 · Most common event earnings